-
How To Finance A Psychedelics Business? Learn From These Four Companies
Tuesday, April 4, 2023 - 4:41pm | 570Read More...Clearmind Medicine Announces Pricing of $3.5 Million Public Offering Israeli biotech company Clearmind Medicine Inc. (NASDAQ: CMND) announced the pricing of its US-only public offering of 4.6 million common shares and pre-funded warrants and 4.5 million common warrants for expected gross...
-
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
Tuesday, January 24, 2023 - 7:01pm | 665Read More...Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) has begun an investigative study on the dissociative effect of a proprietary and patent-pending formulation of (S)-ketamine, as well as an optimized...
-
Potential Road To At-Home Psychedelics Use Permits: Low Dosing's Positive Outcomes In Phase 1 Trial
Monday, December 12, 2022 - 4:55pm | 418Read More...Canadian drug development company Diamond Therapeutics Inc. announced it has successfully completed its Phase 1 clinical study on low-dose psilocybin and shared the trial’s most relevant results. The Toronto-based company is focused on sub-perceptual, non-hallucinogenic treatments that...
-
Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up
Monday, August 23, 2021 - 9:01am | 768Read More...Beckley Psytech Closes $80 Million Series B Beckley Psytech announced the closing of a £58 million ($80 million) Series B raise, which will be used to further finance the company’s psilocybin and 5-MeO-DMT research into neuropsychiatric disorders. The financing was upsized from an...
